Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Theragnostics Ltd
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Group A: Adenocarcinoma of the prostate gland suitable for radical Tx.
Adenocarcinoma of Prostate
Gleason score 4+3 and above, or PSA \> 20 ng/mL or clinical stage \>T2C.
Suitable for surgical tx
No Hormone Therapy in last 3 months
Group B: PCa and a diagnosis of BCR, previously treated with radical prostatectomy, being considered for radical salvage therapy (with curative intent).
Original diagnosis of PCa, treated with radical curative therapy at least 3 months before enrolment, and has been diagnosed with BCR based on:
1. Post RP: two consecutive rises in PSA and final PSA \>0.lng/ml OR Post RP: three consecutive rises in PSA. This definition is also applicable to subjects with PSA persistence post RP (where the PSA fails to fall to undetectable levels).
2. Post RP: PSA doubling time of \~15 months OR PSA level 0.5 ng/ml.
No previous recurrences of PCa.
Consideration for radical salvage therapy.
Should not have received androgen-deprivation therapy within 3 months of screening.
No Hormone Therapy in last 3 months
Group C: PCa and a diagnosis of BCR, previously treated with radical radiotherapy, being considered for radical salvage therapy (with curative intent).
The subject has had an original diagnosis of PCa and underwent radical curative therapy at least 3 months before enrolment, and has been diagnosed with BCR on the basis of:
Increase in PSA level \~2.0 ng/ml above the nadir level after radiotherapy (RT) or brachytherapy, no previous recurrences of BCR.
The subject is being considered for radical salvage therapy.
Should not have received androgen-deprivation therapy within 3 months of screening.
No hormone therapy within the past three months.
You may not be if
Group A:
Prior Tx for Prostate Tumours
Gleason \< 4+3
Hip prostheses
eGFR \<20
Group B:
Hormone Therapy in the last 3 months
Hip prostheses
eGFR \<20
Group C:
Hormone Therapy in the last 3 months
Hip prostheses
eGFR \<20
Clareo Health | 68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer
